Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689807 | 1.00 | CES2 (0.43) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL10686722 | 0.84 | CES2 (0.48) | CES2CES1ALDH1A1 | |
| SCHEMBL14654919 | 0.82 | CES2 (0.56) | CES2CES1 | |
| SCHEMBL24478517 | 0.80 | CES2 (0.59) | CES2CES1TSHRALDH1A1 | |
| SCHEMBL4758346 | 0.80 | CES2 (0.59) | CES2CES1TSHRALDH1A1 | |
| SCHEMBL8090670 | 0.80 | CES2 (0.59) | CES2CES1TSHRALDH1A1 | |
| SCHEMBL7913100 | 0.77 | CES2 (0.47) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL103348 | 0.77 | — | — | |
| SCHEMBL269873 | 0.77 | — | — | |
| SCHEMBL18416515 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12011871-B2 | Processes for formation of porous biologically compatible scaffold structures | XEROX CORPORATION (US) | 2024-06-18 | — | — | US | claimed |
| US-20230021181-A1 | PROCESSES FOR FORMATION OF POROUS BIOLOGICALLY COMPATIBLE SCAFFOLD STRUCTURES | Genesee Valley Innovations, LLC | 2023-01-19 | — | — | US | claimed |
| US-20200189177-A1 | PROCESSES FOR FORMATION OF POROUS BIOLOGICALLY COMPATIBLE SCAFFOLD STRUCTURES | Genesee Valley Innovations, LLC | 2020-06-18 | — | — | US | claimed |
| US-7704929-B2 | Diaromatic amine derivatives as antioxidants | CHEMTURA CORPORATION (US) | 2010-04-27 | — | — | US | claimed |
| US-20070155633-A1 | Diaromatic amine derivatives as antioxidants | LANXESS SOLUTIONS US INC. | 2007-07-05 | — | — | US | claimed |
| EP-1276804-B1 | LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME | UNIROYAL CHEM CO INC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050282878-A1 | Process for the purification of fluconazole | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-12-22 | — | — | US | claimed |
| US-6706216-B1 | REACTION PRODUCT OF CATALYTIC REDUCTIVE ALKYLATION OF P-PHENYLENEDIAMINE OR DERIVATIVE WITH ACETONE AND SECOND CARBONYL COMPOUND | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | claimed |
| US-6706217-B2 | OBTAINED FROM THE REACTION OF A PARAPHENYLENEDIAMINE COMPOUND WITH ACETONE AND AT LEAST ONE OF KETONES AND ALDEHYDES, USING A REDUCTIVE ALKYLATION CATALYST | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | claimed |
| US-20020061946-A1 | Liquid antiozonants and rubber compositions containing same | ADDIVANT USA, LLC | 2002-05-23 | — | — | US | claimed |
| US-20260132232-A1 | OPHTHALMIC DEVICES | BAUSCH LOMB IRELAND LTD (IE) | 2026-05-14 | — | — | US | disclosed |
| EP-3788084-B1 | OPHTHALMIC DEVICES CONTAINING UV BLOCKER AND METHODS FOR THEIR PREPARATION | BAUSCH & LOMB (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12552883-B2 | Ophthalmic devices | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-02-17 | — | — | US | disclosed |
| EP-4677398-A1 | CONTACT LENS CONTAINING DEPROTECTED ULTRAVIOLET BLOCKERS | Bausch + Lomb Ireland Limited (IE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4646240-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | Bausch + Lomb Ireland Limited (IE) | 2025-11-12 | — | — | EP | disclosed |
| US-6706216-B1 | REACTION PRODUCT OF CATALYTIC REDUCTIVE ALKYLATION OF P-PHENYLENEDIAMINE OR DERIVATIVE WITH ACETONE AND SECOND CARBONYL COMPOUND | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6706217-B2 | OBTAINED FROM THE REACTION OF A PARAPHENYLENEDIAMINE COMPOUND WITH ACETONE AND AT LEAST ONE OF KETONES AND ALDEHYDES, USING A REDUCTIVE ALKYLATION CATALYST | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20020061946-A1 | Liquid antiozonants and rubber compositions containing same | ADDIVANT USA, LLC | 2002-05-23 | — | — | US | disclosed |
| US-4900868-A | Process for producing N,N'-disubstituted paraphenylene diamine mixtures by sequential reductive alkylation | MONSANTO COMPANY (US) | 1990-02-13 | — | — | US | disclosed |
| EP-0084527-A2 | Process for producing paraphenylenediamine mixtures | MONSANTO COMPANY (US) | 1983-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282878-A1 | Process for the purification of fluconazole | ERG28, CYP51A1, MAN2B1 | CES2 811/4885CES1 1041/4885HDAC3 3141/4885 |
| US-20260132232-A1 | OPHTHALMIC DEVICES | MYO1G, CRY1, UACA | CES2 3730/4885CES1 1624/4885HDAC3 1068/4885 |
| US-20070155633-A1 | Diaromatic amine derivatives as antioxidants | C9, C5, C1S | CES2 1378/4885CES1 1483/4885HDAC3 1224/4885 |
| US-12552883-B2 | Ophthalmic devices | ILK, MYLK, SMAD2 | CES2 4234/4885CES1 3213/4885HDAC3 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.